The efficacy and safety of γ-linolenic acid in the treatment of atopic dermatitis was evaluated. The children (mean age, 11.4 months) with atopic dermatitis (mean duration, 8.56 months) were openly treated with 3 g/day γ-linolenic acid, for 28 days. Clinical evaluations were carried out every 7 days, and parents were asked to keep a diary, recording details of symptoms of eczema every day. Blood chemistry and immunological tests were done before and after treatment. None of the children showed complete recovery of symptoms. A gradual improvement in erythema, excoriations and lichenification was seen; significant differences were shown for itching (P < 0.01), and the use of antihistamines (P < 0.01). A significant rise in the percentage of circulating CD8 was found. No side-effects were recorded. Dietetic and pharmacological approaches are the basis of the treatment of atopic dermatitis and γ-linolenic acid appears to be a safe and efficient additional therapy for infants and young children.
KjellmannM: Food allergy treatment and prevention. Ann Allergy1987; 59: 168–174.
2.
HansenAE: Serum lipids in eczema and other pathological conditions. Am J Dis Child1937; 53: 933–946.
3.
MorsePF, HorrobinDF, MankuMS: Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema. Relationship between plasma essential fatty acid changes and clinical response. Br J Dermatol1989; 121: 75–90.
4.
CampRDR: Prostaglandins, hydroxy fatty acids, leukotrienes and inflammation of the skin. Clin Exp Dermatol1982; 7: 435–444.
5.
LindskovR, HolmerG: Polyunsaturated fatty acids in plasma, red blood cells and mononuclear cell phospholipids of patients with atopic dermatitis. Allergy1992; 47: 517–521.
6.
WrightS: Atopic dermatitis and essential fatty acids: a biochemical basis for atopy?Acta Derm Venereol (Suppl)1985; 114: 143–145.
7.
MankuMS, HorrobinDF, MorseNL: Essential fatty acids in the plasma phospholipids of patients with atopic eczema. Br J Dermatol1984; 110: 634–639.
8.
BordoniA, BiagiPL: Diomogammalinolenic acid in treatment of atopic dermatitis. Drugs Exp Clin Res1987; 14: 291–295.
9.
BordoniA, BiagiPL, MasiM: Evening primrose oil in the treatment of children with atopic eczema. Drugs Exp Clin Res1987; XIV (4): 291–297.
10.
Schalin-KMoa, LeenaM, JansenCT, UotilaP: Evening primrose oil in the treatment of atopic eczema: effect on clinical status, plasma phospholipid fatty acids and circulating blood prostaglandins. Br J Dermatol1987; 117: 11–19.
11.
HanifinJM, RajkaG: Diagnostic features of atopic dermatitis. Acta Derm Venereol (Suppl)1980; 92: 44–47.
12.
MolkhouP, DupontC: Ketotifen treatment of atopic dermatitis and other food allergy diseases. Allergy1989; 44: 117–123.
HanifinJM: Standardized grading of subjects for clinical research studies in atopic dermatitis: workshop report. Acta Derm Venereol (Suppl)1989; 144: 28–30.
16.
BahmerFA, SchaferJ, SchubertHJ: Atopic dermatitis area and severity index: the ADASI score. Arch Dermatol1991; 127: 1239–1240.
BiagiP, BordoniA, MasiM: A long-term study on the use of evening primrose oil in atopic children. Drugs Exp Clin Res1988; XIV (4): 285–290.
19.
JublinL, JohanssonSGO, BennichH: Immunoglobulin E levels in atopic dermatitis, urticaria and various dermatitides. Arch Dermatol1978; 100: 12–16.
20.
StrannegardI-L, SvennerholmL, StrannegardO: Essential fatty acids in serum lecithin of children with atopic dermatitis and umbilical cord serum of infants with high or low IgE levels. Int Arch Allergy Appl Immunol1987; 82: 422–423.
CariniC, BrostoffJ: An antiglobulin IgG anti-IgE. Occurrence and specificity. Ann Allergy1983; 51: 251–255.
23.
QuintiI, BrozeckC, WoodH: Circulating IgG auto antibodies to IgE in atopic syndrome. J Allergy Clin Immunol1986; 77: 486–491.
24.
CariniC, FratazziC, BarbatoM: IgG autoantibody to IgE in atopic patients. Ann Allergy1988; 60: 48–52.
25.
WhermannW, ReinholdU, PawelecG: In vitro generation of IFN-gamma in relationship to in vivo concentration of IgE and IgG subclasses and Fc-epsilon RI/CD23 positive circulating lymphocytes in patients with severe atopic dermatitis. Acta Derm Venereol (Suppl) (Stockh)1989; 144: 127–130.
26.
ByromNA, TimlinDM: Immune status in atopic eczema: a survey. Br J Dermatol1979; 100: 491–498.
27.
MacDonaldDM, ZacharyC: Quantitative analysis of T lymphocyte subsets in atopic eczema using monoclonal antibodies and flow cytofluorimetry. Br J Dermatol (in press).
28.
BrennerRR: Effect of unsaturated acids on membrane structure and enzyme kinetics. Progr Lipid Res1984; 23: 69–96.
29.
HorrobinDF, MankuMS, OkaM: The nutritional regulation of T-lympho-cyte function. Mec Hypotheses1989; 20: 941–947.
30.
HorrobinDF: The regulation of prostaglandin biosynthesis: negative feed-back mechanism and selective control of 1 and 2 serie prostaglandins: relevance to inflammation and immunity. Med Hypotheses1980; 2: 687–709.
